CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024

Core Insights - Cardiol Therapeutics reported earnings per share of -10 cents, which met the analyst estimate for EPS of -10 cents [3] - The company did not report any revenue for the quarter [3] Financial Performance - Earnings per share (EPS) for the first quarter of 2024 was -10 cents, aligning with analyst expectations [3] - No revenue was generated during the quarter, indicating potential challenges in revenue generation [3]